The purpose of the study is to look at the safety, tolerability, and efficacy of NNZ-2591 in the treatment of children with Phelan-McDermid syndrome.

This study investigates an oral medication called “NNZ-2591”, which aims to improve the impaired connections and signaling between brain cells that are involved in Phelan-McDermid syndrome. The study medication is experimental.